Fig. 5.

Angiostatic monotherapy results in compensatory up-regulation of proangiogenic factors; combination therapy reduces such up-regulation. (A) Solutions consisting of PBS, monotherapies, or triple combination angiostatic therapy were injected into developing mouse eyes (P7) and protein expression levels of angiogenic factors were analyzed by an ELISA-based assay (P11). Stars and crosses indicate individual P values <0.05 compared with PBS-injected controls, or triple combination-treated retinas, respectively. (B) Statistical analyses of overall protein expression changes demonstrate that T2 and VEGF aptamer monotherapy treatments resulted in significant global increases in proangiogenic factor expression compared with PBS control-treated and triple combination-treated retinas.